ArticleTrends in parasitology2021
Pneumocystis pneumonia in the COVID-19 pandemic era: similarities and challenges.
Article in Trends in parasitology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- A diagnostic model for discrimination between Pneumocystis jirovecii pneumonia and colonization based on multiple parameters.Scientific reports · 2026Article
- Post-COVID-19 severeThe Journal of international medical research · 2025Review
- Comparative Dosing of Adjunctive Corticosteroids Therapy forInfection and drug resistance · 2024Article
- The conventional diagnosis challenge: Real-time PCR and nested PCR correlation with the scoring system for individuals at high-risk of Pneumocystis jirovecii pneumonia.Biomedica : revista del Instituto Nacional de Salud · 2023Article
- Trends in the Epidemiology ofJournal of fungi (Basel, Switzerland) · 2023Review
- COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit Patients from Poland.Journal of fungi (Basel, Switzerland) · 2023Article
- Article
- CT imaging of HIV-associated pulmonary disorders in COVID-19 pandemic.Clinical imaging · 2023Review
- Post-COVID-19 Fungal Infection in the Aged Population.Vaccines · 2023Review
- Review
- Post-COVID-19Access microbiology · 2023Article
- Molecular and microscopy detection ofFrontiers in medicine · 2023Article
- Fungal Infections Other Than Invasive Aspergillosis in COVID-19 Patients.Journal of fungi (Basel, Switzerland) · 2022Review
- Case Report: Pneumonia in a Patient With Combined Variable Immunodeficiency: COVID-19 or Pneumocystis Pneumonia?Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical picture of the fungal disease, Pneumocystis pneumonia, resembles the course of coronavirus disease 2019 (COVID-19), presenting a diagnostic challenge in the pandemic era. We discuss the concern of Pneumocystis jirovecii and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coinfection, their similarities, and the impact of immunosuppression, with a suggested diagnostic pathway for their suspected coinfection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.